Summary of the Conference Call for Meihow Medical Company Overview - Meihow Medical focuses on medical device CDMO, covering areas such as respiratory care, cochlear implants, blood glucose management, and cardiovascular surgical interventions, with full-process production capabilities and relevant qualifications [2][3] Key Business Segments - The company has made significant progress in cochlear implants, utilizing a sound processor to convert external sounds into multiple frequency bands, transmitted to the inner ear via platinum wires, with a unit price of approximately $1,000 and a gross margin of 60%-70% [2][6] - Meihow Medical is developing implantable brain-machine interface (BMI) devices, leveraging its cochlear implant experience, with expected gross margins similar to cochlear implants once mass production begins [2][7] Brain-Machine Interface Technology - BMI technology is categorized into output, input, and interactive types, with applications in medical rehabilitation, mental health, education, and entertainment [4][5] - The company anticipates BMI new business revenue to reach millions to tens of millions of RMB by 2025, with potential for significant growth in 2026 [4][16] Market Outlook - In 2026, Meihow Medical expects a recovery in its main business, with double-digit growth in home respiratory devices and cochlear implants, and above-average growth in blood glucose and consumer segments [4][22] - The company’s BMI products are still in the early industrial stage, with current revenue from cochlear implants around 100 million RMB, 50% of which comes from invasive electrode pieces [15] Collaboration and Client Relationships - 90% of Meihow Medical's business comes from overseas exports, with collaborations with leading companies in the BMI field [17][18] - The company has established a strong reputation due to its long-term experience in processing Class III materials, which is a key consideration for clients when selecting suppliers [19] Challenges and Innovations - Long-term implant technology is a complex system engineering challenge, requiring integration of process technology to ensure stability under long-term conditions [21] - The company is also exploring semi-invasive and non-invasive products, aiming to enhance the effectiveness of non-invasive devices through invasive technology [12][13] Future Developments - Meihow Medical is expanding into humanoid robotics, leveraging existing technologies and planning to fill production capacity in emerging consumer electronics markets [25] - The company’s Malaysian factory is expected to stabilize profit margins and net profits as production scales up [24] Conclusion - Overall, Meihow Medical is positioned for growth in the medical device sector, particularly in cochlear implants and brain-machine interfaces, with a strong focus on innovation and collaboration with industry leaders [2][4][16]

Q&A 脑机接口产业目前的市场行情如何？有哪些关键因素推动了这一领域的发展？ 最近脑机接口市场行情非常火爆，主要是由于国内出台了利好政策，以及马斯 克在社交媒体上表示 Neuralink 将在 2026 年大规模生产脑机接口设备。这些 因素共同引爆了整个板块的情绪。脑机接口产业的发展关键在于快速商业化落 地，尤其是在非侵入式领域，企业需要具备强大的销售渠道能力、品牌力以及 与原有医疗业务的协同效应，以促进商业化落地速度和后续发展。 脑机接口产业更新及重点标的推荐 20260106 摘要 脑机接口产业正快速发展，商业化落地是关键，尤其在非侵入式领域， 企业需具备强大的销售渠道、品牌力及与原有医疗业务的协同效应，以 加速商业化进程。预计到 2025 年全球市场规模将达 30 亿美元，医疗 端应用将在 2030 年超过 400 亿美元。 脑机接口技术路径包括侵入式、半侵入式和非侵入式。侵入式信号质量 高但风险大，适用于重症患者；非侵入式安全性高，商业化快但竞争激 烈；半侵入式介于两者之间。美国企业多布局半侵入式，中国企业则以 非侵入式为主。 Neuralink 在侵入式脑机接口领域领先，已完成约 20 例人体植入， ...

Group 1: Report Investment Ratings - The investment rating for the stock index is "volatile", and for the treasury bond is "relatively strong" [1] Group 2: Core Views - The market showed an upward trend with the Shanghai Composite Index rising above 4000 points and the ChiNext Index rising nearly 3%. The CSI A500 index rose over 2%, reaching a new high since January 2022. The A500ETF had significant net subscriptions, while the net short positions of the top 5 member units in IF increased. The relevant funds may not have significant net outflows after the New Year. In the short - term, the stock index is expected to remain within the oscillation range formed since October. The cumulative year - on - year revenue growth rate of the constituent stocks of the CSI 1000 in the third quarter was about 2.6%, which supports the current valuation and reduces the risk of liquidity. The spring rally may not be as intense as in previous years [1] - The main contracts of treasury bonds declined on Tuesday. The central bank conducted 16.2 billion yuan of 7 - day reverse repurchases, with a net withdrawal of 296.3 billion yuan. The short - term money market is reasonably abundant, which is the biggest support for the bond market, but the stable economy, rising inflation, and cautious attitude towards interest rate cuts pose certain constraints. The bond market is expected to remain range - bound in the short term [1][2] Group 3: Daily Price Changes Stock Index Futures | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | IH | 3,161.8 | 3,098.8 | 63.0 | 2.03% | | IF | 4,778.0 | 4,697.0 | 81.0 | 1.72% | | IC | 7,786.4 | 7,596.0 | 190.4 | 2.51% | | IM | 7,762.4 | 7,639.0 | 123.4 | 1.62% | [3] Stock Indexes | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | Shanghai Composite 50 | 3,158.8 | 3,099.7 | 59.0 | 1.90% | | CSI 300 | 4,790.7 | 4,717.7 | 72.9 | 1.55% | | CSI 500 | 7,814.1 | 7,651.2 | 162.9 | 2.13% | | CSI 1000 | 7,864.9 | 7,753.9 | 111.0 | 1.43% | [3] Treasury Bond Futures | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | TS | 102.37 | 102.41 | - 0.048 | - 0.05% | | TF | 105.57 | 105.71 | - 0.135 | - 0.13% | | T | 107.70 | 107.86 | - 0.155 | - 0.14% | | TL | 110.93 | 111.32 | - 0.39 | - 0.35% | [3] Group 4: Market News - On January 6, the Shanghai Composite Index had 13 consecutive positive days, reaching a ten - year high, with a 1.5% increase. The Shenzhen Component Index rose 1.4%, and the ChiNext Index rose 0.75%. The trading volume of the Shanghai and Shenzhen stock markets was 2.81 trillion yuan, an increase of 260.2 billion yuan from the previous trading day. The brain - computer interface sector had a daily limit surge, and sectors such as insurance, securities, and non - ferrous metals were also strong [4] - From 2024 to 2025, China achieved 18.3 million units of automobile trade - ins, with new energy vehicles accounting for nearly 60%, and 192 million units of home appliance trade - ins, with first - level energy - efficiency (water - efficiency) products accounting for over 90%. The trade - in policy drove consumer sales of 3.92 trillion yuan, benefiting 494 million consumers [4] Group 5: Chart Analysis Stock Index Futures - The report provides charts of the trends of IH, IF, IM, IC main contracts, and their respective monthly basis trends [5][6][7] Treasury Bond Futures - The report provides charts of the trends of treasury bond futures main contracts, treasury bond spot yields, basis of different - term treasury bond futures, inter - period spreads of different - term treasury bond futures, cross - variety spreads, and money market rates [12][13][14] Exchange Rates - The report provides charts of the central parity rates of the US dollar, euro against the RMB, forward exchange rates of the US dollar and euro against the RMB, US dollar index, euro - US dollar exchange rate, pound - US dollar exchange rate, and US dollar - yen exchange rate [21][22][23]

（文章来源：证券时报网） 数据宝统计，截至09:38，美好医疗成交额17.05亿元，创上市以来新高。最新股价上涨17.70%，换手率 11.03%。上一交易日该股全天成交额为1.36亿元。（数据宝） ...

公司发布的三季报数据显示，前三季度公司共实现营业收入11.94亿元，同比增长3.28%，实现净利润 2.08亿元，同比下降19.25%，基本每股收益为0.3700元，加权平均净资产收益率5.79%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 美好医疗股价创出历史新高，截至9:34，该股上涨20.01%，股价报41.56元，成交量2909.21万股，成交 金额12.09亿元，换手率7.80%，该股最新A股总市值达236.42亿元，该股A股流通市值155.10亿元。 证券时报•数据宝统计显示，美好医疗所属的医药生物行业，目前整体涨幅为0.33%，行业内，目前股价 上涨的有224只，涨停的有美好医疗、嘉事堂等4只。股价下跌的有245只，跌幅居前的有麦澜德、百花 医药、锦好医疗等，跌幅分别为11.30%、9.97%、9.37%。 两融数据显示，该股最新（1月6日）两融余额为1.37亿元，其中，融资余额为1.35亿元，近10日减少 515.71万元，环比下降3.67%。 ...

Group 1 - The stock of Meihao Medical has achieved a three-day limit-up, indicating strong market interest and trading activity, with a transaction amount of 2.597 billion yuan and a turnover rate of 16.90% [1] - In the brain-computer interface sector, the company is collaborating with downstream clients to transition from laboratory development to mass production, leveraging its expertise in cochlear implant technology [1] - In the artificial intelligence sector, the company is integrating PEEK manufacturing, precision molds, and sensor technology to develop humanoid robots, with surgical robots already being supplied in small batches to domestic and international clients [1] Group 2 - The company is a leading player in the global home ventilator market, with a projected revenue growth of 25.58% for home ventilator components in 2024 compared to the previous year [1] - In the cochlear implant sector, the company is a top player in the CDMO market, with revenue from implanted cochlear components increasing by 18.74%, serving clients who are leaders in their respective niche markets [1]

Market Overview - The Shanghai Composite Index opened slightly higher at 4083.84 points, showing a minor increase compared to the previous closing price [1] - Active sectors included brain engineering, commercial aerospace, and Beidou navigation, with notable stocks such as Meihua Medical and Nanjing Panda hitting the daily limit up [1] Stock Performance - Several stocks achieved consecutive limit-up gains, including: - Zhejiang Shibao (14 days, 7 limit-ups) related to Xiaomi and Changan Automobile concepts [1] - Shengtong Energy (13 days, 13 limit-ups) linked to natural gas and mergers & acquisitions [1] - Fenglong Co. (8 days, 8 limit-ups) associated with Changan Automobile and new energy vehicle concepts [1] - Other stocks with consecutive limit-ups include: - Lixin Investment (8 days, 6 limit-ups) in venture capital and sugar substitute concepts [1] - YB Duct (4 days, 4 limit-ups) in new urbanization and brokerage concepts [1] - Various stocks in AI, brain-machine interface, and satellite navigation concepts also showed strong performance [1] Opening Trends - Stocks that opened high included: - BeiYikang (high open of 14.56%) in financing and brain-machine interface concepts [1] - Zhitex New Materials (high open of 8.32%) [1] - Seli Medical (high open of 7.0%) in cell immunotherapy concepts [1] - Stocks that opened low included: - Nongxin Technology (low open of 10.01%) [1] - Yuyin Co. (low open of 4.96%) in internet finance and facial recognition concepts [1] - Nanxing Co. (low open of 4.29%) in AIGC and AI agent concepts [1]

Group 1 - The brain-computer interface sector opened high again, indicating strong investor interest and market momentum [1] - Companies such as Beiyikang and Meihao Medical reached new highs, reflecting positive performance and growth potential [1] - Innovative Medical, Nanjing Panda, and Yanshan Technology achieved three consecutive trading limit ups, showcasing significant market enthusiasm [1] Group 2 - Sanbo Brain Science and Daoshi Technology also experienced upward movement, indicating a broader trend of growth within the sector [1]

Core Insights - The report emphasizes the strong growth potential in the electronic materials sector, driven by rapid advancements in downstream industries, continuous technological iterations, and the backdrop of domestic substitution [2][6][10] - The mechanical equipment industry is expected to benefit from structural technological growth, particularly in high-end manufacturing, with a focus on sectors like controlled nuclear fusion and humanoid robots [12][14][17] Electronic Materials Sector - The semiconductor materials market is projected to reach $67.5 billion in sales by 2024, with a year-on-year growth of 3.8%, and is expected to exceed $87 billion by 2029, reflecting a CAGR of 4.5% from 2024 to 2029 [7] - The PCB materials segment is experiencing a shift towards high-frequency and high-speed applications, with the global market for electronic resins and fabrics estimated at approximately $33.02 billion and $24.13 billion respectively in 2023 [8] - The OLED materials market is anticipated to grow significantly, with global sales expected to reach $2.44 billion in 2024 and $8.498 billion by 2031, representing a CAGR of 19.8% from 2025 to 2031 [9] Mechanical Equipment Sector - The controlled nuclear fusion sector is entering a phase of accelerated commercialization, with significant government support and technological breakthroughs expected to drive growth [13][17] - The liquid cooling market is set to expand rapidly due to increasing demands for AI computing power, with liquid cooling becoming essential for future AI servers and data centers [14][17] - The humanoid robot industry is transitioning into mass production, with several companies achieving order and delivery milestones, indicating a growing market for related components [15][17] Tourism and Social Services - Domestic tourism showed strong growth during the New Year holiday, with 142 million domestic trips taken, reflecting a 5.2% increase year-on-year, and total spending reaching approximately 84.79 billion yuan, up 6.3% [20][22] - The cross-border travel market is also experiencing significant growth, with a 28.6% increase in the number of people entering and exiting the country during the holiday period [23] Medical and Biological Sector - The brain-computer interface market is gaining traction, with companies like Neuralink planning large-scale production of devices by 2026, indicating a growing interest in this emerging field [26][28][30] - Domestic companies are making strides in the brain-computer interface space, with over 200 firms reported to be involved, highlighting the potential for significant advancements in this technology [29][30]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in investor interest, driven by technological breakthroughs and product approvals in China, alongside Elon Musk's announcement of mass production of BCI products by Neuralink within the year [1][3]. Industry Developments - The BCI industry is in a high-growth phase, supported by technological advancements, policy backing, and collaborative expectations within the robotics ecosystem, with projections indicating the global BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040 [3]. - Recent breakthroughs include the first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology, which offers hope for patients with severe paralysis [3][4]. Company Responses - Multiple A-share listed companies have responded to the heightened interest in the BCI sector, with announcements detailing their business progress in this area [1][6]. - Xiangyu Medical reported a 44% cumulative increase in stock price, emphasizing its focus on non-invasive BCI technology, while acknowledging that its products have not yet achieved significant sales [6][9]. - Weisi Medical also clarified that its BCI products are in the early market cultivation stage and primarily focus on non-invasive technologies, with limited revenue contribution [9][10]. Strategic Collaborations - Companies are actively forming partnerships to enhance their BCI capabilities. Baiyang Pharmaceutical announced a collaboration with Capital Medical University to establish a joint laboratory focused on neuroscience and BCI research [11]. - Kefu Medical disclosed investments in non-invasive BCI robotics and implantable BCI companies, aiming for business synergy [11]. Technological Innovations - Companies like Sanbo Brain Science are making progress with their BCI technologies, including the development of a flexible microelectrode system for brain signal acquisition [12]. - In the semiconductor sector, companies are producing specialized chips for high-precision measurement of biological signals, which are essential for BCI applications [13]. Market Recognition - Domestic BCI products are gaining international recognition, with Shenzhou Rehabilitation's spinal interface product receiving breakthrough therapy designation from the FDA, marking a significant achievement for Chinese companies in the BCI field [4].